Company news
Veracyte, Inc. news in 2022
Veracyte, Inc.'s news releases, calls and decks from 2022, newest first.
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
December 14, 2022
Veracyte Announces Third Quarter 2022 Financial Results
November 1, 2022
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
October 31, 2022
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
October 26, 2022
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
October 24, 2022
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
October 23, 2022
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
October 17, 2022
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
October 12, 2022
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
September 21, 2022
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
September 12, 2022
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
September 10, 2022
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
September 6, 2022
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
August 31, 2022
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
August 30, 2022
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
August 10, 2022
Veracyte Announces Second Quarter 2022 Financial Results
August 1, 2022
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
July 19, 2022
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
July 13, 2022
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
July 12, 2022
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
June 26, 2022
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
June 19, 2022
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
June 2, 2022
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
May 30, 2022
Veracyte to Present at Upcoming Investor Conferences
May 25, 2022
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
May 25, 2022
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
May 25, 2022
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
May 15, 2022
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
May 11, 2022
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
May 11, 2022
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
May 3, 2022
Veracyte Announces First Quarter 2022 Financial Results
May 2, 2022
Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
May 1, 2022
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
April 27, 2022
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
April 25, 2022
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
April 18, 2022
Veracyte to Participate in the Cowen 42nd Annual Health Care Conference
February 28, 2022
Veracyte Appoints Annie McGuire as General Counsel
February 27, 2022
Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results
February 27, 2022
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
February 21, 2022
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
February 14, 2022
New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer
February 13, 2022
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
February 7, 2022
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
January 30, 2022
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
January 23, 2022
Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
January 5, 2022
Calls in 2022
Decks in 2022
- Q1 2022 Earnings Presentation
Earnings · 15 slides · May 3, 2022